Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate the efficacy and safety of deferiprone compared to deferasirox in paediatric patients aged from 1 month to less than 18 years of age affected by transfusion-dependent haemoglobinopathies

Trial Profile

Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate the efficacy and safety of deferiprone compared to deferasirox in paediatric patients aged from 1 month to less than 18 years of age affected by transfusion-dependent haemoglobinopathies

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Deferiprone (Primary) ; Deferasirox
  • Indications Haemosiderosis
  • Focus Therapeutic Use
  • Acronyms DEEP-2

Most Recent Events

  • 06 Nov 2019 Results asessing neutropenia in children treated with Deferiprone or Deferasirox released in the 61st Annual Meeting and Exposition of the American Society of Hematology.
  • 19 Oct 2017 Status changed from active, no longer recruiting to completed.
  • 21 Mar 2017 Planned End Date changed from 1 Apr 2017 to 1 Aug 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top